Eric D Whitman1, Frank Xiaoqing Liu2, Xiting Cao2, Scott J Diede2, Amin Haiderali2, Amy P Abernethy3. 1. Atlantic Melanoma Center, Atlantic Health System Cancer Care, 100 Madison Ave., Morristown, NJ 07960, USA. 2. Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ 07033, USA. 3. Flatiron Health, Inc., 233 Spring St, New York, NY 10013, USA.
Abstract
AIM: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). METHODS: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. RESULTS: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3-23.3). CONCLUSION: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.
AIM: To describe recent evolution in treatment patterns and outcomes for advanced melanoma (AMel). METHODS: This retrospective observational study analyzed de-identified electronic health record data from the Flatiron Health database for 1140 adult patients who initiated first-line therapy for AMel from 1 January 2014 to 30 June 2016 with follow-up through 28 February 2017. RESULTS: The most common first-line regimens were ipilimumab-based therapies (34%), anti-PD-1 monotherapy (26%) and BRAF/MEK inhibitor(s) (20%). First-line ipilimumab-based and BRAF inhibitor regimens decreased after the third quarter of 2014 (3Q2014), and by 2Q2016, 55 and 91% of BRAF-mutant and BRAF wild-type cohorts, respectively, received a first-line anti-PD-1 regimen. Median overall survival from first-line initiation for all patients was 18.8 months (95% CI: 16.3-23.3). CONCLUSION: Results illustrate changing paradigms of therapy and real-world patient outcomes for AMel.
Authors: C Lance Cowey; Frank Xiaoqing Liu; Marley Boyd; Kathleen M Aguilar; Clemens Krepler Journal: Medicine (Baltimore) Date: 2019-07 Impact factor: 1.817
Authors: Daniel M Sheinson; William B Wong; Craig S Meyer; Stella Stergiopoulos; Katherine T Lofgren; Carlos Flores; Devon V Adams; Mark E Fleury Journal: JAMA Netw Open Date: 2021-12-01
Authors: Charles L Cowey; Marley Boyd; Kathleen M Aguilar; April Beeks; Clemens Krepler; Emilie Scherrer Journal: Cancer Med Date: 2020-09-01 Impact factor: 4.452
Authors: Adi Kartolo; Jasna Deluce; Wilma M Hopman; Linda Liu; Tara Baetz; Scott Ernst; John G Lenehan Journal: Curr Oncol Date: 2022-03-01 Impact factor: 3.677
Authors: Susan Spillane; Shrujal Baxi; Aracelis Z Torres; David Lenis; Andrew N Freedman; Angela B Mariotto; Elad Sharon Journal: Oncologist Date: 2020-10-03 Impact factor: 5.837